Your Trading Needs Fresh Ideas?
We work for your Profit

Technical Analysis, Share Price Target, Support, Resistance, Charts of Dr Reddys Labs

Latest Updates on Dr Reddys Laboratories

Dr Reddys Labs on 15-02-17 was on news, according to the report Dr reddys labs recall its drug "Olanzapine tablets USP of 2.5 mg" from US markets after notification issued by US food and drug authority. Dr reddy is recalling 5904 bottles of Olanzapine 30 counts bottles from the market.

Dr Reddys Labs share gained smartly on 02nd February 2017 and closed with a gain of 3.19% and closed at 3097.05 (+95.85) after company CEO Saumen Chakraborty said that they are not worries about Trump`s comment on drug pricing. Moreover they are waiting for final blue print and that will determine the company's manufacturing and expansion plans in the United States

As per latest news on 26th January 2017, South Korean biotech firm Mezzion Pharma files suit against Dr Reddys Labs in US court, alleging that it hid significant deficiencies in Food and Drug Administration practices and misrepresented its compliance.